Moderna kicks off Phase 1 trial of 3 different mRNA HIV vaccines
Comment of the Day

March 17 2022

Commentary by Eoin Treacy

Moderna kicks off Phase 1 trial of 3 different mRNA HIV vaccines

This article from NewAtlas may be of interest to subscribers. Here is a section:

“Finding an HIV vaccine has proven to be a daunting scientific challenge,” said NIAID director Anthony Fauci, in a statement announcing the Phase 1 trial. “With the success of safe and highly effective COVID-19 vaccines, we have an exciting opportunity to learn whether mRNA technology can achieve similar results against HIV infection.”

The Phase 1 trial will enroll around 100 healthy adults, with the initial goal of evaluating the safety and immune responses to three different mRNA vaccine formulations. Each subject will receive three doses of their assigned mRNA formulation over a six-month period.

In the same way mRNA COVID-19 vaccines are designed to train the immune system to respond to the spike protein on the surface of SARS-CoV-2, these experimental vaccines focus on the HIV equivalent of the spike protein antigen target, known as an envelope glycoprotein trimer.

This protein on the surface of HIV particles is much more complex that the coronavirus spike protein, so Moderna has developed three different mRNA formulations to test, each encoding for a slightly different protein architecture.

The trial is expected to run until mid-2023. By that point it is hoped one of the three formulations will have demonstrated robust immune responses and Phase 2 trials can commence.

Eoin Treacy's view

This announcement holds out promise that an intransigent health issue can be addressed with a shot. It also highlights the fact that rushed permitting for COVID-19 vaccines is not about to be repeated. If the trials schedule discussed in the above article is followed, it will be a decade before a potential solution reaches market. It is also likely to be held to a much higher standard of proof.

Click HERE to subscribe to Fuller Treacy Money Back to top